CiVi Biopharma Holding Corp. is a clinical-stage research and development biotechnology company whose mission is to create novel cardiovascular and metabolic therapies that have meaningful value to patients. The company has multiple assets in various stages of development. Through its wholly-owned subsidiary, Eicos Sciences, Inc., CiVi Biopharma is advancing intravenous iloprost in Phase 3 clinical trials for the treatment of Systemic Sclerosis. In addition, CiVi is in Phase 2 clinical development of CiVi 007, a next-generation PCSK9, for the treatment and prevention of cardiovascular disease and is in the early-stage development of CiVi 020, a highly selective and potent PPARδ agonist, for a variety of rare diseases. Founded in 2017, by Chief Scientific Officer, Henrik Oerum, and led by Chief Executive Officer, Shal Jacobovitz, the company is headquartered in Chevy Chase, MD.